Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Soleno Therapeutics (SLNO) to $81 from $70 and keeps a Buy rating on the shares following the FDA approval of Vykat XR. By 2030, the firm estimates Vykat XR revenues will reach $1.6B in the U.S. alone, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics price target raised to $102 from $72 at Baird
- Soleno Therapeutics price target raised to $105 from $75 at Laidlaw
- Soleno price target raised to $123 at Cantor Fitzgerald after VYKAT XR approved
- Aardvark Therapeutics price target raised to $26 from $22 at BofA
- Soleno Stock (SLNO) Soars 32% after FDA Greenlights New Drug
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue